©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
High Affinity Binding of -Adrenergic Receptor Kinase to Microsomal Membranes
MODULATION OF THE ACTIVITY OF BOUND KINASE BY HETEROTRIMERIC G PROTEIN ACTIVATION (*)

(Received for publication, September 14, 1995; and in revised form, October 30, 1995)

Cristina Murga (2)(§) Ana Ruiz-Gómez (2) Irene García-Higuera (2)(¶) Chong M. Kim (1) Jeffrey L. Benovic (1) Federico Mayor Jr. (2)(**)

From the  (1)From theDepartment of Pharmacology, Jefferson Cancer Institute, Thomas Jefferson University, Philadelphia, Pennsylvania 19107 and the (2)Centro de Biología Molecular ``Severo Ochoa,'' Consejo Superior de Investigaciones Científicas-Universidad Autónoma, 28049 Madrid, Spain

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

The beta-adrenergic receptor kinase (betaARK) modulates beta-adrenergic and other G protein-coupled receptors by rapidly phosphorylating agonist-occupied receptors at the plasma membrane. We have recently shown that betaARK also associates with intracellular microsomal membranes both ``in vitro'' and ``in situ'' (García-Higuera, I., Penela, P., Murga, C., Egea, G., Bonay, P., Benovic, J. L., and Mayor, F., Jr. (1994) J. Biol. Chem. 269, 1348-1355), thus suggesting a complex modulation of the subcellular distribution of betaARK. In this report, we used recombinant [S]methionine-labeled betaARK to show that this kinase interacts rapidly with a high affinity binding site (K of 20 ± 1 nM) present in salt-stripped rat liver microsomal membranes. Although betaARK binding is not modulated by membrane preincubation with G protein activators, the activity of bound betaARK toward rhodopsin or a synthetic peptide substrate was markedly enhanced upon stimulation of the endogenous heterotrimeric G proteins present in the microsomal membranes by AlF(4) or mastoparan/guanosine 5`-(3-O-thio)triphosphate, thus strongly suggesting a functional link between these proteins and membrane-associated betaARK. Interestingly, betaARK association with microsomal membranes is not significantly affected by a fusion protein derived from the carboxyl terminus of betaARK1 (the proposed location of the beta subunit binding site), whereas it is markedly inhibited by fusion proteins corresponding to the amino-terminal region of the kinase. The main determinants of binding appear to be localized to an 60-amino acid residue stretch (residues 88 to 145). Our results further indicate a functional relationship between betaARK and heterotrimeric G proteins in different intracellular organelles, and suggest that additional proteins may be involved in modulating the cellular localization of the kinase through a new targeting domain of betaARK.


INTRODUCTION

A general feature of G protein-coupled receptors is that exposure to agonists often leads to a rapid loss of receptor responsiveness, a process termed desensitization or tolerance. Such regulatory mechanisms are triggered every time a receptor is activated and play a key role in signal integration and plasticity at the cellular level. The beta-adrenergic receptor (betaAR)(^1)-coupled adenylyl cyclase system has provided an important model for the study of the molecular mechanisms of desensitization (Benovic et al., 1988; Dohlman et al., 1991; Kobilka, 1992; Lohse, 1993). Work from several laboratories has shown that rapid agonist-specific desensitization of the betaAR is due to functional uncoupling from the transducing G protein, which is initiated by phosphorylation of the betaAR by beta-adrenergic receptor kinase (betaARK), a serine-threonine kinase that specifically phosphorylates the agonist-occupied form of the receptor (Palczewski and Benovic, 1991; Lefkowitz, 1993; Haga et al., 1994a). betaARK-mediated phosphorylation allows the interaction with the betaAR of an additional regulatory protein, beta-arrestin, which precludes receptor interaction with G proteins and blocks signal transduction (Lohse et al., 1990; Kobilka, 1992). The uncoupling process is followed by transient receptor internalization away from the plasma membrane. Interestingly, emerging evidence indicates that betaARK may be able to modulate a variety of G protein-coupled receptors (Benovic et al., 1987; Kim et al., 1993b; Kwatra et al., 1993; Richardson et al., 1993). This, together with the recent characterization of different betaARK-related kinases, which constitute the G protein-coupled receptor kinase (GRK) multigene family, strongly suggests that very similar mechanisms of regulation operate for all G protein-coupled receptors (Inglese et al., 1993; Haga et al., 1994a; Loudon and Benovic, 1994; García-Higuera et al., 1994b).

However, there is little understanding of the protein-protein interactions of this complex regulatory network, and of the changes in the subcellular distribution of these proteins that take place upon receptor activation. betaARK has been described as a soluble, cytosolic enzyme that transiently translocates to the plasma membrane when the receptor is occupied by an agonist (Strasser et al., 1986; Mayor et al., 1987; García-Higuera and Mayor, 1992; Chuang et al., 1992). Recent data indicate that beta subunits of heterotrimeric G proteins are able to enhance betaARK activity toward different G protein-coupled receptors (Haga and Haga, 1992; Pitcher et al., 1992; Kameyama et al., 1993; Kim et al., 1993b), and both purified G proteins and isolated beta subunits can interact with betaARK in vitro (Pitcher et al., 1992; Kim et al., 1993b). Therefore, it has been proposed that the interaction of beta subunits with betaARK would help to target the kinase to the periphery of the plasma membrane and to increase its activity toward the activated receptor. The beta-binding domain of betaARK has been localized to a 125-amino acid stretch in the COOH-terminal region of the enzyme (Kameyama et al., 1993; Koch et al., 1993); this region partially overlaps with a pleckstrin homology domain present in betaARK (Touhara et al., 1994). Moreover, we have recently reported that, in addition to being a soluble enzyme that transiently translocates to the plasma membrane, a significant amount of betaARK is associated with internal microsomal membranes in a variety of tissues and cell lines (García-Higuera and Mayor, 1994; García-Higuera et al., 1994a), thus raising new questions regarding the functional role of this kinase. Subcellular fractionation studies and indirect immunofluorescence and immunogold electron microscopy localization in cultured cells confirmed the association of betaARK with microsomal structures in situ (García-Higuera and Mayor, 1994; García-Higuera et al., 1994a). In our previous report, cell-free association experiments indicated that betaARK peripherally associates with a protein component of the microsomal membranes by means of electrostatic interactions (García-Higuera et al., 1994a), in a way reminiscent of its transient interaction with the plasma membrane.

In this paper, we have used a direct binding assay with [S]methionine-labeled betaARK (Kim et al., 1993b) to further characterize the kinase binding site in the microsomes and investigated the functional consequences of such interaction. Our data support a functional link between betaARK and microsomal heterotrimeric G proteins and suggest the existence of a new targeting domain of betaARK involved in the modulation of the complex subcellular distribution of this important regulatory kinase.


EXPERIMENTAL PROCEDURES

Preparation of Rat Liver Subcellular Fractions

Subcellular fractionation of rat liver was performed essentially as described (García-Higuera and Mayor, 1994; García-Higuera et al., 1994a). Briefly, adult male Wistar rats were sacrificed by decapitation, and their livers were rapidly excised, weighed, minced and homogenized with a motorized Teflon pestle in 4 volumes of ice-cold buffer A (20 mM Tris-HCl, pH 7.4, 5 mM EDTA, 5 mM EGTA, 1 mM phenylmethylsulfonyl fluoride, 20 µg/ml leupeptin, 20 µg/ml benzamidine) plus 250 mM sucrose. All subsequent manipulations were performed at 4 °C. The supernatant of a low speed centrifugation (250 times g, 4 min) was centrifuged at 3,000 times g for 10 min to obtain a plasma membrane pellet. After centrifugation of the supernatant at 10,000 times g for 20 min to obtain the crude mitochondrial pellet, the microsomal membrane pellet was obtained by centrifuging the postmitochondrial supernatant for 60 min at 250,000 times g in a Beckman TL-100 centrifuge. The plasma membrane and the microsomal membranes were washed once in buffer A, and the final pellets resuspended in buffer A supplemented with 200 mM NaCl and incubated for 30 min at 4 °C in order to extract betaARK activity (García-Higuera and Mayor, 1992; García-Higuera et al., 1994a). After centrifugation as above, betaARK-stripped plasma or microsomal membrane aliquots were resuspended to a protein concentration of 15 mg/ml in buffer A and stored at -70 °C. Electron microscopy and enzymatic marker characterization of these subcellular fractions indicated that crude plasma membranes display a 6.7-fold increase in the activity of the specific marker 5`-nucleotidase with respect to the homogenate, whereas microsomal fractions are enriched in endoplasmic reticulum, lysosomal and Golgi apparatus enzymatic activities, with little contamination by plasma membrane (García-Higuera et al., 1994a; García-Higuera and Mayor, 1994).

Purification of betaARK and Radiolabeling with [S]Methionine

Bovine betaARK was overexpressed in Sf9 cells using the baculovirus expression system and purified from high-speed supernatant fractions of cell homogenates by sequential chromatography on SP-Sepharose and heparin-Sepharose columns exactly as described previously (Kim et al., 1993a). For radiolabeling, infected Sf9 cells were incubated for 20 h in methionine-free Graces media containing 1-2 mCi of [S]methionine (1190 Ci/mmol) and then harvested and purified exactly as previously reported (Kim et al., 1993b). Purity of radiolabeled betaARK was >95%, as judged by SDS-polyacrylamide gel electrophoresis. The radiolabeled betaARK was stored at -20 °C and used at a specific activity of 350-1000 cpm/pmol.

Purification of G Protein beta Subunits

After purification of G(i) and G(o) from bovine brain membranes as described (Sternweis and Robishaw, 1984), beta subunits were isolated by chromatography on heptylamine-Sepharose in the presence of AMF (30 µM AlCl(3), 6 mM MgCl(2), and 10 mM NaF) (Katada et al., 1984) followed by anion exchange chromatography on a Mono Q column to obtain subunits free of AMF and cholate (Kim et al., 1993b). The purified beta was stored in 20 mM Tris-HCl, pH 8.0, 1 mM EDTA, 1 mM dithiotreitol, 150 mM NaCl, and 0.05% Lubrol at -80 °C.

Analysis of G Protein Subunits in Rat Liver Membrane Fractions

The presence of heterotrimeric G proteins in the plasma and microsomal membrane fractions used in our betaARK binding and activity experiments was investigated by [S]GTPS binding as previously reported (Northup et al., 1982). The presence of alpha and beta subunits was also investigated by immunoblot analysis after resolving the membrane fractions (30-70 µg of protein) by electrophoresis on 11% SDS-polyacrylamide gels and electroblotting to nitrocellulose filters, using as probes the G protein alpha subunit alpha antibody AS8 (1:300 dilution, a generous gift from Drs. G. Shültz and K. Spicher, Free University, Berlin), the beta subunit beta antibody M-14 (5 µg/ml, Santa Cruz Biotechnology) or the beta subunit antibody MS/1 (1:300, DuPont NEN) as described (Koch et al., 1993). Similar results were obtained with the different beta subunit antibodies. The blots were developed using a chemiluminescence method (ECL, Amersham Corp.). In the latter case, an approximate quantitation of the presence of beta subunits was performed by simultaneously probing known amounts (20-40 ng) of purified bovine beta subunits (see above) resolved in the same gel, and densitometric analysis using a Molecular Dynamics laser densitometer.

Preparation of GST-betaARK Fusion Proteins

Fusion proteins containing amino acids 50-145 (FP1) or 437-689 (FP2) of bovine betaARK1 were prepared essentially as reported (Koch et al., 1993). Specific 5` and 3` polymerase chain reaction primers (containing BamHI and EcoRI restriction sites, respectively) were used to amplify the desired cDNA fragments. The amplified fragments were ligated in frame between the BamHI and EcoRI sites of the glutathione S-transferase (GST) gene fusion vector pGEX-2T (Pharmacia). Additional GST-betaARK1 constructs comprising amino acids 1-63, 1-88, 1-122, or 1-147 were prepared in a similar way. Selected clones were verified by dideoxy sequencing using T7 DNA-Polymerase (Sequenase, Stratagene). The fusion protein constructs were used to transform the Escherichia coli strain AG1 induced with isopropyl-1-thio-beta-D-galactopyranoside, and proteins were purified by affinity chromatography on glutathione-Sepharose 4B (Pharmacia). The integrity of the purified fusion proteins (or GST alone) was analyzed by SDS-PAGE and Coomassie Blue staining.

Analysis of beta Binding to GST-betaARK Fusion Proteins

Detection of possible interactions between purified G protein beta subunits and our fusion proteins was performed as described (Koch et al., 1993; Inglese et al., 1994). Briefly, purified bovine brain beta subunits (150 nM) were incubated for 30 min at 4 °C with the desired betaARK fusion proteins (or GST as a negative control) at a final concentration of 1 µM in 50 µl of 20 mM Tris-HCl, pH 7.4, 1 mM MgCl(2), 0.01% Lubrol. Then, 20 µl of a 50% slurry of glutathione-Sepharose 4B were added, and incubation continued for 90 min in ice with gentle mixing. The beads were washed three times with 1 ml of buffer containing 0.01% Lubrol, and retained proteins were analyzed by SDS-PAGE on 11% acrylamide gels, followed by transfer to nitrocellulose and Western blot analysis with antibodies against beta subunits as described above, using purified beta subunits run in the same gel as a positive control.

betaARK Binding to Microsomal Membranes

S-Labeled betaARK (5-80 nM) was incubated in buffer A or in 20 mM Tris-HCl, pH 7.4, in reaction volumes of 100-300 µl (Kim et al., 1993b) with 0.4-0.75 µg/µl salt-stripped microsomal membranes (which do not contain any residual betaARK). In some experiments, microsomal membranes were preincubated for 15-30 min at 37 °C in 20 mM Tris-HCl, pH 7.4, 2 mM MgCl(2) alone, or in the presence of different concentrations of MgCl(2), cAMP, heparin, AlF(4), GDP, mastoparan, and GTPS (as indicated in the figure legends), or different concentrations (5-30 µM) of bovine serum albumin, GST, or GST-betaARK fusion proteins. The binding mixtures were incubated at 37 °C for 0.5-15 min, and membrane-associated betaARK was collected by centrifugation at 250,000 times g for 10-30 min at 4 °C in a Beckman TL-100 centrifuge. The microsomal membrane pellets were carefully washed with buffer and then solubilized with 1% SDS and counted with scintillation fluid. In some experiments, the radioactivity of the supernatant containing unbound betaARK was also quantitated. Nonspecific binding was defined by performing the binding reaction in the presence of 200 mM NaCl, an experimental condition in which betaARK association with a protein component of the microsomal membrane has been shown to be completely inhibited (García-Higuera et al., 1994a). S-Labeled betaARK binding can also be competed by unlabeled recombinant betaARK (data not shown). In other experiments, unlabeled recombinant betaARK was used as the ligand, and bound betaARK was determined as described by immunoblot analysis with specific antibodies raised against betaARK (García-Higuera and Mayor, 1994; García-Higuera et al., 1994a). Alternatively, the extent of betaARK binding under different experimental conditions was assessed by quantitating the kinase activity remaining in the soluble fraction after high-speed centrifugation by using the rhodopsin phosphorylation assay as described (García-Higuera et al. (1994a), also see below).

Effect of Na(2)CO(3) Treatment on betaARK Association with Microsomal Membranes

Aliquots of stripped microsomal membranes were resuspended in equal volumes of 100 mM Na(2)CO(3), pH 11, or buffer A and incubated for 30 min at 4 °C in order to extract peripheral membrane proteins, as described (Fujiki et al., 1982). The amount of beta subunits of heterotrimeric G proteins remaining in the membranes or released by the treatment was determined by immunoblot analysis as described above. Control and treated membranes were subsequently washed in buffer A and its ability to interact with betaARK was assessed as described (García-Higuera et al., 1994a). The presence of betaARK in the soluble and particulate fractions was determined by the rhodopsin phosphorylation assay as reported (Mayor et al.(1987) and García-Higuera et al. (1994a), also see below), by using the direct S-labeled betaARK binding assay as detailed above, or by utilizing recombinant unlabeled betaARK followed by immunoblot analysis as described (García-Higuera et al., 1994a).

Determination of betaARK Activity

betaARK activity was assessed by using either a synthetic peptide substrate or purified urea-treated rod outer segments, as described previously in our laboratories (Benovic et al., 1986; Mayor et al., 1987; Kim et al., 1993b). Rhodopsin kinase-free purified rod outer segments consisting on >90% rhodopsin as indicated by Coomassie Blue staining of polyacrylamide gels were prepared in the dark as reported (Benovic et al., 1986), and aliquots containing 120 pmol of rhodopsin were incubated for 20-30 min at 30 °C in a buffer containing 27 mM Tris, pH 7.5, 1.4 mM EDTA, 1 mM EGTA, 5.5 mM MgCl(2), 4.5 mM NaF, 57 µM [-P]ATP (2-3 cpm/fmol) plus 20 nM recombinant bovine betaARK in the presence or absence of 17-70 µg of microsomal or plasma membrane proteins (final volume 60 µl). Before testing its effect on betaARK activity toward rhodopsin, the desired amount of stripped microsomal or plasma membranes were preincubated (10 min at 37 °C in 20 mM Tris-HCl, pH 7.5, 1 mM MgCl(2)) alone or in the presence of the heterotrimeric G protein activators AlF(4) (5 mM NaF, 50 µM AlCl(3), 100 µM GDP) or mastoparan (100 µM) plus GTPS (25-50 µM). Reactions were started by exposure to fluorescent laboratory lighting and stopped by 20-fold dilution with ice-cold 20 mM Tris-HCl followed by centrifugation. The resultant rhodopsin-containing pellets were resuspended in SDS-PAGE sample buffer and resolved by electrophoresis on 12% polyacrylamide gels followed by autoradiography. betaARK activity was quantitated by measuring the radioactivity associated with the excised rhodopsin band in the dried gel by Cerenkov spectroscopy (Mayor et al., 1987). betaARK activity was also investigated using a synthetic peptide as substrate. The peptide RRREEEEESAAA was synthesized on a Applied Biosystems 431A synthesizer using Fmoc (N-(9-fluorenyl)methoxycarbonyl) chemistry. The peptide (1 mM) was incubated for 30 min with betaARK (20 nM) in the absence or presence of 0.6 µg/µl stripped microsomal or plasma membrane proteins, in a buffer containing 20 mM Tris-HCl, pH 7.5, 2 mM EDTA, 7.5 mM MgCl(2), 100 µM [-P]ATP (0.5-1 cpm/fmol) in a final volume of 55 µl at 30 °C. Before starting the experiment, the stripped microsomal or plasma membranes were preincubated (15 min at 37 °C in 20 mM Tris-HCl, pH 7.5, 1 mM MgCl(2)) alone or in the presence of the heterotrimeric G protein activators AlF(4) (5 mM NaF, 50 µM AlCl(3), 100 µM GDP) or mastoparan (20-100 µM) plus GTPS (50 µM). Reactions were stopped by addition of 30 µl of 30% trichloroacetic acid. The quenched reactions were centrifuged at 48,000 times g for 10 min and the resulting supernatants were transferred to a 2 times 2-cm square of P-81 paper followed by washes in 75 mM phosphoric acid and radioactivity quantitation as described (Kim et al., 1993b).


RESULTS

Previous studies from our laboratory have shown that betaARK is associated with microsomal membranes in rat liver and many other tissues and cell lines (García-Higuera et al., 1994a). The kinase can be completely extracted from the membranes by mild salt treatment (200 mM NaCl), thus suggesting a peripheral association based on electrostatic interactions. Moreover, we reported (by using activity measurements and immunoblot analysis), that recombinant purified betaARK1 was able to interact with a protein component of salt-stripped rat liver microsomal membranes in a cell-free system (García-Higuera et al., 1994a). In these experiments, membrane-associated and unbound betaARK were separated by centrifugation at 250,000 times g followed by kinase quantitation in the pellet or the supernatant. In order to gain further insight into the mechanisms of association of betaARK with microsomal membranes, we have utilized a direct binding assay using purified recombinant [S]methionine-labeled betaARK1, which has recently been used for investigating the interaction of betaARK with phospholipid vesicles containing purified G protein subunits (Kim et al., 1993b). In the assays shown below, S-labeled betaARK was incubated under different experimental conditions with stripped rat liver microsomal membranes, and the amount of membrane-associated betaARK was then determined by measuring the radioactivity in the high-speed pellets. Nonspecific binding of betaARK was estimated by performing parallel experiments in the presence of 200 mM NaCl, a condition known to completely inhibit the kinase binding to the microsomal vesicles (García-Higuera et al., 1994a). This has enabled a quantitative and detailed characterization of the interaction of betaARK with this physiological membrane preparation.

Fig. 1A shows that betaARK binding to stripped microsomal membranes is very rapid (half-maximal binding achieved in less than 1 min) and results in the association of most (75%) of the kinase present in the assay. Scatchard analysis (Fig. 1B) indicates that the interaction process is saturable and appears to involve one population of high affinity binding sites (K(d) of 20 ± 1 nM). Similar results are obtained using lower concentrations of membranes. Interestingly, such kinetic and affinity data are similar to those reported for the interaction of betaARK1 with purified heterotrimeric G proteins or beta subunits (58 ± 14 and 32 ± 5 nM, respectively) (Kim et al., 1993b). In order to better understand betaARK association with microsomal membranes, we tried to obtain further information on the type of proteins(s) responsible for the interaction, on the effect of binding on betaARK activity, and on possible modulators of betaARK association and function.


Figure 1: Characterization of S-labeled betaARK binding to stripped microsomal membranes. A, time course of direct binding. Labeled betaARK (20 nM, 500 cpm/pmol) was incubated in buffer A with stripped microsomal membranes (0.56 µg of protein/µl) at 37 °C for the times indicated and membrane-associated betaARK was determined after high-speed centrifugation as detailed under ``Experimental Procedures.'' Specific binding was the difference between counts in the absence and presence of 200 mM NaCl. Data points are the mean ± S.E. of two independent experiments done in duplicate. B, representative Scatchard analysis of betaARK binding. Labeled betaARK (5-80 nM, 350 cpm/pmol) was incubated in buffer A with stripped microsomal membranes (0.4 µg of protein/µl) for 15 min at 37 °C and specific binding determined as in panel A. K and B(max) values are the mean ± S.E. of three independent experiments performed in duplicate. A representative saturation curve is shown in the inset (circle, total binding; bullet, nonspecific binding; , specific binding).



Since betaARK binding to G protein subunits has been shown in vitro (Pitcher et al., 1992; Koch et al., 1993; Kim et al., 1993b), and the presence of heterotrimeric G proteins in intracellular organelles is mentioned in an increasing number of reports (see references in Balch(1992), García-Higuera et al. (1994a), and Neubig(1994)), we investigated the presence of endogenous G proteins in the salt-stripped microsomal membranes used in our studies. Specific alpha and beta subunit antibodies detect major bands of 40- and 35-kDa, respectively (Fig. 2), thus confirming the presence of heterotrimeric G proteins in this preparation. G proteins can also be detected in the microsomal membranes by a S-labeled GTPS binding assay (data not shown). The identity of the subunit isoforms has not been investigated in detail, although additional protein bands in the 40-46 kDa range can be detected with the alpha antibody at longer times of exposure. With regard to beta subunits, comparison of the signal obtained in microsomal membranes with that of a known amount of beta subunits purified from bovine brain (Fig. 2, lane 1) allows an approximate quantitation of at least 10 pmol of microsomal beta per mg of stripped membrane protein, in the same order of magnitude as the B(max) detected for betaARK binding (see Fig. 1B).


Figure 2: Presence of alpha and beta subunits of heterotrimeric G proteins in rat liver stripped microsomal membranes. Stripped microsomal membranes (60 µg of protein, lanes 1 and 3) or 20 ng of purified beta subunits obtained from bovine brain (lane 2) were resolved by 11% SDS-PAGE, blotted to nitrocellulose membranes, and probed with antibodies AS8 (alpha subunit antibody, 1/300, lane 3) or M14 (beta subunit antibody, 5 µg/ml, lanes 1 and 2). Results are representative of three experiments.



We next tested the ability of different compounds to modulate betaARK association with microsomal membranes using the direct binding assay. Particularly, we investigated whether betaARK interaction would be modulated by known G protein activators. In initial experiments, preincubation of stripped microsomal membranes with the selective heterotrimeric G protein activator AlF(4) (Finazzi et al., 1994) in the presence of excess Mg and GDP promoted a marked increase in subsequent betaARK binding (Fig. 3A). However, this effect seems to be due only to the presence of Mg and not to G protein activation, since a similar increase in betaARK interaction is observed when only Mg is added during the preincubation (Fig. 3A); GDP alone has no effect on betaARK binding (data not shown). A more detailed investigation on the effect of Mg was performed. Fig. 3B shows a dose-dependent effect of submillimolar concentrations of Mg on betaARK association with the microsomal membranes, which reaches an 4-fold increase over control binding at 1 mM Mg. Such fold-increase is similar to that observed in Fig. 3A at 2.5 mM Mg, thus suggesting that the Mg effect attains a maximum in such concentration range. The presence of Mg promotes an increase in the apparent B(max) (65 pmol/mg of protein with 1 mM Mg) without changing the affinity of betaARK for its binding sites. The divalent cation Mn can substitute for Mg (70% of Mg effect at 1 mM Mn). In order to optimize betaARK binding and to approach physiological intracellular concentrations, 1 mM MgCl(2) was routinely included in all subsequent experiments.


Figure 3: Modulation of S-labeled betaARK binding to microsomal membranes. A, stripped microsomal membranes (0.75 µg of protein/µl) were preincubated for 15 min at 37 °C in buffer A in the absence(-) or presence (+) of 12.5 mM MgCl(2) and/or AlF(4) (5 mM NaF, 50 µM AlCl(3), 1 mM GDP) and then incubated for 2 min at 37 °C in the presence of S-labeled betaARK (20 nM, 500 cpm/pmol) in a final volume of 300 µl. Specific betaARK binding was determined as in Fig. 1. Data are mean ± S.E. of six independent experiments. B, effect of magnesium on betaARK binding: S-labeled betaARK (20 nM, 500 cpm/pmol) was incubated for 5 min at 37 °C in the presence of stripped microsomal membranes (0.75 µg of protein/µl) in a buffer containing 20 mM Tris-HCl, pH 7.5, in the absence or presence of the indicated concentrations of MgCl(2). Specific binding was determined as detailed in Fig. 1and under ``Experimental Procedures.'' Bound betaARK in the absence of MgCl(2) (1.14 ± 0.2 pmol of betaARK/mg of protein) was taken as the basal value to which all the other experimental conditions were referred. Data are mean ± S.E. of two independent experiments performed in duplicate.



The fact that betaARK binding to microsomal membranes is not modulated by known G protein activators is further confirmed by the lack of effect on betaARK association of mastoparan, a tetradecapeptide which stimulates guanine nucleotide exchange and activates heterotrimeric G proteins (Higashijima et al., 1988; Colombo et al., 1992) or GTPS, a non-hydrolyzable GTP analog which is a general activator of G proteins (Colombo et al., 1992; Tsai et al., 1992) (data not shown). The presence of other nucleotides such as GDP, ATP, GTP, or App(NH)p (0.5-1 mM) did not have any effect on betaARK binding, and did not promote the release of previously bound betaARK from the microsomal membranes (data not shown). Other possible modulatory compounds, such as cAMP or heparin, a betaARK inhibitor (Benovic et al., 1989a), do not significantly modulate betaARK interaction. The association of the kinase with the stripped microsomal membranes is reduced by 50% when tested in the presence of 100 mM potassium gluconate, an ionic condition similar to the intracellular medium (not shown, see also García-Higuera et al. (1994a)). In summary, our data indicate that despite its presence in microsomal membranes and the previously reported interaction with betaARK in vitro (Pitcher et al., 1992) G protein activation was not required and did not modulate betaARK binding in our model.

We have previously shown (García-Higuera et al., 1994a) that betaARK association to microsomal membranes is reversible, i.e. that previously extracted or recombinant betaARK1 can interact with salt-stripped microsomes, thus indicating that the microsomal component involved in the interaction is not removed during the mild stripping procedure. Fig. 4A shows that when salt-stripped membranes are further treated with 0.1 M Na(2)CO(3) at pH 11, a commonly used method for removing strongly-attached peripheral membrane proteins (Fujiki et al., 1982; Yu et al., 1992), betaARK association (as assessed by an activity assay) is not affected, thus suggesting that betaARK interacts with a microsomal component which behaves as an integral membrane protein. A more detailed and quantitative analysis of the interaction of betaARK with Na(2)CO(3)-stripped membranes was performed. Immunoblot analysis indicates that the interaction of recombinant betaARK with a defined amount of salt-stripped microsomal membranes (Fig. 4B, lane 1) is not altered after removal of additional peripheral proteins with the Na(2)CO(3) pH 11 treatment (lane 2); the association with the Na(2)CO(3)-stripped membranes is blocked in the presence of 200 mM NaCl (lane 3). Direct binding studies using 50 nMS-labeled betaARK show that a given amount of microsomal membranes retains 86 ± 9% (mean ± S.D. of two independent experiments performed in triplicate) of specific kinase binding after the Na(2)CO(3) pH 11 treatment, thus leading to an 1.5-fold increase in binding specific activity (up to 82 ± 5 pmol/mg protein). Similar results were obtained in other sets of assays using 25 nM labeled betaARK. It is worth noting that the Na(2)CO(3) treatment leads to the loss of 50% of the G protein beta subunits from the membranes, as assessed by immunoblot analysis (Fig. 4C). The fact that such 50% decrease in G protein subunits does not alter betaARK association suggests that G proteins may not be the main anchor for betaARK in the microsomal membranes (also see below).


Figure 4: Influence of microsomal membrane pretreatment with Na(2)CO(3) on betaARK association and on the presence of G protein beta subunits. A, study of betaARK association by using an activity assay. Stripped microsomal membranes were resuspended in buffer A or in 100 mM Na(2)CO(3), pH 11, and incubated for 30 min at 4 °C in order to extract remaining peripheral proteins. After one wash in buffer A, control and treated membranes were incubated for 10 min at 37 °C with a similar amount of a soluble extract containing betaARK activity exactly as described (García-Higuera, et al., 1994). Soluble and membrane-associated betaARK were separated by centrifugation and betaARK activity in the supernatant (S) and microsomal membrane (M) fractions was determined by using a rhodopsin phosphorylation assay as detailed under ``Experimental Procedures.'' The arrow indicates the position of phosphorylated rhodopsin. B, immunoblot analysis of betaARK association. Aliquots of salt-stripped microsomal membranes were treated in the absence (lane 1) or presence (lanes 2 and 3) of Na(2)CO(3) pH 11 as indicated under ``Experimental Procedures'' and extracted proteins separated by high-speed centrifugation. The same volume of membrane pellets (corresponding to 50 µg of protein in the initial, non Na(2)CO(3)-treated membranes) were resuspended in 20 mM Tris-HCl, pH 7.5, 2 mM MgCl(2) and incubated for 5 min at 37 °C with 30 nM recombinant betaARK in the absence (lanes 1 and 2) or presence (lane 3) of 200 mM NaCl. After centrifugation at 250,000 times g for 10 min, the amount of bound betaARK in each sample was assessed by immunoblot analysis as detailed under ``Experimental Procedures.'' 80 ng of recombinant betaARK were directly resolved and analyzed in the same gel as a control (lane 4). Results are representative of two independent experiments. C, presence of G protein beta subunits in microsomal membranes subjected to different stripping procedures. Salt-stripped purified microsomal membranes (800 µg of protein) were treated in the absence (lanes 2 and 3) or presence (lanes 4 and 5) of Na(2)CO(3) pH 11 as indicated under ``Experimental Procedures'' in a final volume of 800 µl. After high-speed centrifugation to separate membranes and extracted proteins, equivalent aliquots of the membrane pellets (60 µg of proteins, lanes 2 and 4) and extracted supernatants (60 µl, lanes 3 and 5) were resolved by 11% SDS-PAGE, blotted to nitrocellulose membranes, and probed with a beta subunit antibody (M14, Santa Cruz Biotechnology, 5 µg/ml) as described under ``Experimental Procedures.'' 60 µg of unstripped microsomal membranes (lane 1) and 20 ng of purified beta subunits obtained from bovine brain (lane 6) were resolved and blotted in the same gel and probed as above.



We next investigated the functional consequences of betaARK binding to the microsomal membranes by comparing the activity of the free and bound kinase toward exogenous substrates. Fig. 5shows that, compared to free betaARK (lane 1), a marked inhibition of light-dependent rhodopsin phosphorylation is observed in the presence of increasing amounts of microsomal membranes (lanes 3-5), which do not show any residual betaARK activity (lane 2). This result indicates that bound betaARK is less able to interact with rhodopsin and/or to phosphorylate this membrane-bound specific substrate. It is worth noting that the same effect is observed when a synthetic peptide substrate is used to test the activity of betaARK (Fig. 7A), thus showing that the observed effect is not restricted to the rhodopsin phosphorylation assay. Interestingly, it has been reported that rhodopsin phosphorylation by the homologous, if not identical, muscarinic acetylcholine receptor kinase was strongly inhibited by heterotrimeric G proteins in the absence of guanine nucleotides in a dose-dependent way (Haga and Haga, 1992).


Figure 5: Effect of the presence of different concentrations of microsomal membrane proteins on the phosphorylation of rhodopsin by betaARK. Recombinant betaARK (20 nM) was preincubated alone or in the presence of the indicated amounts of stripped microsomal membranes in 20 mM Tris-HCl, pH 7.5, 1 mM MgCl(2) in a final volume of 50 µl for 10 min at 37 °C. The phosphorylation reaction (30 min, 30 °C) was initiated by the sequential addition of phosphorylation buffer and purified rod outer segments to give the final concentrations detailed under ``Experimental Procedures'' (final volume, 60 µl). Phosphorylated rhodopsin was resolved by SDS-PAGE and visualized by autoradiography. Results are representative of three independent experiments.




Figure 7: The activity of betaARK toward a synthetic peptide substrate is modulated by the presence of stripped microsomal or plasma membrane fractions and by heterotrimeric G protein activators. Stripped microsomal (panel A) or plasma (panel B) membrane fractions (0.6 µg of protein/µl) were preincubated for 15 min at 37 °C in the presence of 20 nM betaARK in 20 mM Tris-HCl, pH 7.5, 1 mM MgCl(2), alone or in the presence of AlF(4) (5 mM NaF, 50 µM AlCl(3), 100 µM GDP) or mastoparan (20 or 100 µM) and GTPS (50 µM). The activity of bound betaARK toward the synthetic peptide substrate RRREEEEESAAA was subsequently assessed for 30 min at 30 °C, after the sequential addition of peptide substrate and phosphorylation buffer to give the final concentrations detailed under ``Experimental Procedures.'' After determination of the radioactivity incorporated into the peptide, the activity of betaARK in the presence of stripped microsomal membranes (0.7 ± 0.17 pmol of phosphate incorporated) or stripped plasma membranes (0.6 ± 0.28 pmol of phosphate incorporated) alone were taken as the basal values to which all the other experimental conditions were referred. Data are mean ± S.E. of two to four independent experiments performed in duplicate.



Since purified beta subunits or stimulators of G protein activation and dissociation such as GTPS have been shown to stimulate betaARK activity toward different substrates (Haga and Haga, 1992; Pitcher et al., 1992: Müller et al., 1993; Pei et al., 1994), we next investigated whether preincubation of stripped microsomal membranes with specific agents that would activate endogenous heterotrimeric G proteins may modulate the activity of bound betaARK. Fig. 6A shows that the marked inhibition of betaARK activity observed in the presence of microsomal membranes (compare lanes 1 and 3) is relieved when the microsomes were previously preincubated with the G protein activators AlF(4) (lane 4) or mastoparan plus GTPS (lane 5). This effect cannot be simply ascribed to a release of bound betaARK, since such compounds do not show any effect on betaARK binding to the microsomal membranes ( Fig. 3and data not shown), and the same result is obtained when the microsomal membranes are pelleted and then resuspended in phosphorylation buffer in the presence of rhodopsin (data not shown), thus indicating a direct effect on bound betaARK as a consequence of G protein activation and subunit dissociation. The same effect can be observed when betaARK functionality is assessed using a synthetic peptide substrate (Fig. 7A). It is interesting to note that similar results were apparent when we used stripped plasma membranes instead of microsomal membranes for these experiments: bound betaARK activity toward either rhodopsin or a peptide substrate was marked inhibited and was only relieved in the presence of heterotrimeric G protein activators (Fig. 6B and 7B). These data suggest a general feature of betaARK interaction with cellular membranes and indicate, for the first time using physiological membrane preparations, that the activity of betaARK is regulated by endogenous G proteins in different intracellular locations.


Figure 6: Activation of endogenous heterotrimeric G proteins present in stripped microsomal or plasma membrane fractions modulate the phosphorylation of rhodopsin by betaARK. Recombinant betaARK (20 nM) was preincubated in the presence of 0.7 µg of protein/µl of either stripped microsomal (A) or stripped plasma membrane fractions (B) as detailed under ``Experimental Procedures'' and in Fig. 5, in the absence or presence of AlF(4) (5 mM NaF, 50 µM AlCl(3), 100 µM GDP) or mastoparan (100 µM) plus GTPS (50 µM), as indicated. The activity of bound betaARK was assessed by the rhodopsin phosphorylation assay as described in the legend to Fig. 5. Results are representative of three independent experiments.



The fact that G protein activation can modulate the activity of bound betaARK clearly demonstrates a functional link between these proteins in the microsomal membranes. Such a functional link could be the consequence of a direct association of betaARK to G proteins under basal conditions, which would result in kinase activation in the presence of specific G protein stimulators. Alternatively, or in addition, betaARK could be binding to a different protein in the stripped microsomes, but its activity may be modulated by additional interactions with G protein beta subunits released upon G protein activation.

Since attempts to directly identify the microsomal protein(s) involved in betaARK interaction using different cross-linkers were unsuccessful, we tried another approach based on investigating the ability of fusion proteins containing different betaARK domains to displace S-labeled kinase association with microsomal membranes. It has been described that the beta binding site domain of betaARK is localized in the COOH-terminal portion of the kinase (Koch et al., 1993; Kameyama et al., 1993) and GST fusion proteins containing the last 222 amino acids of betaARK have been recently used to characterize betaARK interactions with beta subunits (Pitcher et al., 1992; Inglese et al., 1994; Touhara et al., 1994). Therefore, we prepared a similar fusion protein construct (FP2) containing amino acids 437-689 of bovine betaARK1 and an additional construct containing amino acids 50-145 of the kinase (FP1) (see Fig. 8A), which contains a highly charged region that could be involved in electrostatic interactions (Benovic et al., 1989b). The betaARK fusion proteins were expressed in E. coli and purified by affinity chromatography on gluthatione-Sepharose columns; purified GST alone was also prepared as a negative control. As expected, FP2 (encompassing the COOH-terminal portion of betaARK), was able to associate with purified G protein beta subunits isolated from bovine brain, whereas GST alone or FP1 did not associate or showed a very weak interaction (Fig. 8B). Consistently, FP2 blocked beta subunit activation of rhodopsin phosphorylation by betaARK, whereas FP1 had no an inhibitory effect (Fig. 8C). We next investigated whether these proteins could inhibit betaARK association with stripped microsomal membranes by measuring the binding of S-labeled kinase to microsomes preincubated under control conditions or in the presence of different concentrations of GST or GST-betaARK fusion proteins (Fig. 8D). Interestingly, GST-FP2 showed only a very slight effect on betaARK binding over a range of concentrations that have been shown to strongly inhibit betaARK association to purified G protein beta subunits in vitro or to block beta subunit modulation of type II adenylyl cyclase in reconstituted or permeabilized systems (IC in the range 10-20 µM) (Pitcher et al., 1992; Koch et al., 1993; Touhara et al., 1994; Inglese et al., 1994). Similar results were obtained in the presence of G protein activators (data not shown). On the contrary, the fusion protein GST-FP1, containing an amino-terminal region of the kinase, markedly decreased labeled betaARK interaction with the microsomal membranes, with a potency (60% of binding inhibition at 15 µM) similar to that of the COOH terminus on beta-related functions. Interestingly, similar results were obtained when the effects of these fusion proteins on S-labeled betaARK binding were tested in Na(2)CO(3)-stripped membranes, which are partially devoid of G proteins (Fig. 4C and Kehlenbach et al.(1994)) but retain the ability to interact with the kinase (60 ± 5% and 106 ± 8% of control binding of 40 nMS-labeled betaARK in the presence of 20 µM GST-FP1 and GST-FP2, respectively). Taken together, our data indicate that the mechanism of betaARK association with microsomal membranes is different from that of its interaction with G protein beta subunits, and suggest that betaARK is primarily interacting with an additional protein component of the membranes.


Figure 8: Effect of GST-betaARK fusion proteins on S-labeled betaARK binding to microsomal membranes. A, domain structure of bovine betaARK1 indicating the regions from which fusion protein containing amino acids 50-145 (FP1) or 437-689 (FP2) were derived; the proposed location of the pleckstrin homology domain (PH) and the beta subunits binding region are also indicated. B, beta binding properties of GST-betaARK fusion proteins. Purified bovine brain beta subunits were incubated with identical concentrations of GST, FP1, and FP2 and protein complexes pelleted using glutathione-Sepharose beads as indicated under ``Experimental Procedures.'' Bound proteins were resolved by SDS-PAGE, transferred to nitrocellulose, and detected with a specific antibody; purified brain beta subunits (Gbeta) were used as a positive control. C, effect of GST-betaARK fusion proteins FP1 and FP2 on rhodopsin phosphorylation by betaARK in the presence of G protein beta subunits. The rhodopsin phosphorylation assay was performed as described under ``Experimental Procedures''; after incubation for 40 min at 30 °C in the presence of 20 nM recombinant betaARK and 80 nM beta subunits alone or in the presence of 10 µM GST or the indicated GST-betaARK fusion proteins the reaction was stopped by addition of SDS-PAGE buffer, and phosphorylated rhodopsin was resolved by 12% SDS-PAGE followed by autoradiography. D, dose-dependent inhibition of S-labeled betaARK binding to microsomal membranes by GST-betaARK fusion proteins. Stripped microsomal membranes (0.75 µg of protein/µl) were preincubated for 30 min at 37 °C in 20 mM Tris-HCl, pH 7.5, 2 mM MgCl(2) with the indicated concentrations of GST or the fusion proteins FP1 and FP2 or an equivalent amount of bovine serum albumin in the same vehicle (control conditions). Labeled betaARK was then added at a final concentration of 15 nM. After 5 min at 37 °C betaARK specific binding was determined as detailed in Fig. 1and under ``Experimental Procedures.'' Data are expressed as percentage of the binding detected in control conditions, and are means ± S.E. of 3-4 independent experiments performed in duplicate.



In order to confirm these results and start to delineate the region of betaARK involved in the association with microsomal membranes, we tested the effects of additional fusion proteins. In these experiments, microsomal membranes were incubated with recombinant betaARK in the presence of different GST-betaARK constructs (Fig. 9A) and either GST alone or 200 mM NaCl as controls. Membrane-bound and soluble betaARK were separated by high-speed centrifugation, and the betaARK activity remaining in the supernatant was quantitated. Control experiments were performed to show that remaining fusion proteins per se did not have any effect on the phosphorylation assay (data not shown). Fig. 9B show that, as expected, NaCl strongly inhibits betaARK binding to the membranes (i.e. high betaARK activity present in the supernatant), whereas binding is high in the presence of GST (i.e. low betaARK activity remaining in the supernatant), which does not inhibit betaARK association (see Fig. 8D). The presence of GST-betaARK fusion proteins comprising amino acids 1-147 or 50-145 (FP1) clearly inhibits betaARK binding to microsomal membranes, whereas a construct encompassing amino acids 1-88 does not, thus suggesting that the main determinants of betaARK association are located in the region 88-145. Taken together, these results indicate that the interaction of this regulatory kinase with the microsomes preferentially involves a domain located within the amino-terminal portion of betaARK, and suggest that G protein beta subunits are not the main anchor for betaARK in the microsomal membranes.


Figure 9: Analysis of the effect of amino-terminal GST-betaARK fusion proteins on betaARK association with microsomal membranes. A, schematic representation of the GST-betaARK constructs used in the experiments. B, effect of GST-betaARK fusion proteins on betaARK binding to microsomal membranes. Stripped microsomal membranes (0.75 µg of protein/µl) were preincubated for 30 min at 37 °C as detailed in Fig. 8D with the indicated fusion proteins (15 µM) or NaCl 200 mM, and recombinant betaARK was then added at a final concentration of 10 nM. After 5 min at 37 °C, bound and soluble betaARK were separated by high-speed centrifugation as detailed under ``Experimental Procedures,'' and unbound betaARK was quantitated in 5 µl of the supernatants using the rhodopsin phosphorylation assay. Results are representative of five independent experiments.




DISCUSSION

An early step in the regulation of betaAR is the phosphorylation of the agonist-occupied receptor by betaARK, which was initially described as a soluble enzyme that transiently translocates to the plasma membrane upon receptor activation (Lefkowitz, 1993; Inglese et al., 1994; Haga et al., 1994a). Recent data have shown that betaARK can interact with purified beta subunits or whole heterotrimeric G proteins in vitro (Pitcher et al., 1992; Kim et al., 1993b), thus suggesting possible anchors for the kinase in the plasma membrane. In addition, we have recently reported that betaARK associates with internal microsomal membranes both in vitro and in situ (García-Higuera et al., 1994a). These data indicate that several betaARK pools (microsome-bound, plasma membrane-bound, and cytosolic) exist inside the cell and suggest that complex mechanisms (probably involving specific interactions with different proteins) may operate in order to regulate the subcellular distribution and activation of betaARK. In this report, we have further characterized the association of betaARK with microsomal membranes using a direct S-labeled betaARK binding assay, and investigated the modulation of the functionality of the microsome-bound kinase.

Our data indicate that betaARK binds very rapidly to stripped microsomal membranes with a K(d) of 20 nM. The kinase appears to associate with only one population of high affinity binding sites, although the possibility of more than one population of sites with similar binding affinities cannot be completely ruled out. Such binding sites are suggested to be protein components of the microsomal membrane, since previous data from our laboratory showed that protease or heat pretreatment of the microsomes strongly inhibits betaARK association (García-Higuera et al., 1994a). Furthermore, the lack of effect on betaARK binding of Na(2)CO(3) pH 11 treatment shown in the present report indicates that the kinase binding sites behave as integral membrane proteins. It is worth noting that the affinity of betaARK interaction with microsomal membranes is higher than that reported for its association with agonist-activated beta(2)AR (K(d) > 100 nM) and similar to that obtained with purified G proteins (K(d) 58 nM) or isolated beta subunits (K(d) 32 nM) (Kim et al., 1993b), consistent with a functionally relevant role. The present study provides the first report of a high affinity interaction of betaARK with a physiological membrane preparation. Association with microsomal membranes is not unique for betaARK since a number of other proteins (pp60, PKC-, ADP-ribosylation factors, kinesin, and dynein) have been reported to interact in different ways with such types of preparations (Resh, 1989; Chida et al., 1994; Tsai et al., 1992; Yu et al., 1992; Thissen and Casey, 1993).

Given the previously reported interaction of betaARK with purified G proteins and beta subunits and the stimulation of betaARK activity by free beta subunits (see above), these proteins were obvious candidates for participating in betaARK binding and for modulating the activity of microsomal betaARK, since their presence in intracellular membranes has been increasingly appreciated (see references in García-Higuera et al. (1994a), Neubig(1994), and Nuoffer and Balch, 1994). We confirmed by [S]GTPS binding and immunoblot analysis the presence of heterotrimeric G proteins in our preparations, and its preliminary quantitative analysis was compatible with a role in betaARK association, taking into account the apparent B(max) of betaARK binding. However, our results clearly show that the interaction of betaARK with the microsomal membrane is not dependent on heterotrimeric G protein activation, since no significant changes can be observed under experimental conditions routinely used for G protein stimulation (Colombo et al., 1992; Tsai et al., 1992; De Almeida et al., 1993; Kim et al., 1993b). The only apparent modulators of betaARK binding were low millimolar concentrations of divalent cations such as Mg. Since Mg can modulate a variety of enzymatic reactions (including phosphorylation/dephosphorylation processes, although the involvement of proteins kinases as mediators of its effect is unlikely in our experimental conditions), the mechanisms of the Mg effect on betaARK interaction and its possible functional relevance remain to be established.

Our studies on the modulation of the activity of microsome-bound betaARK put forward two interesting findings: (i) the bound kinase is in an inactive state, as shown by its reduced ability to phosphorylate rhodopsin or a synthetic peptide substrate; and (ii) although betaARK binding is not affected by stimulators of heterotrimeric G proteins such as mastoparan/GTPS or AlF(4), these agents promote a marked increase in the activity of bound kinase, indicating a functional link between endogenous microsomal G proteins and betaARK.

It has been previously shown that the phosphorylation of rhodopsin or the muscarinic acetylcholine receptor by rhodopsin kinase or betaARK-like kinases was strongly inhibited by phospholipid vesicles containing purified, non-activated heterotrimeric G proteins (Kelleher and Johnson, 1988; Haga and Haga, 1990, 1992), and that this effect was relieved in the presence of GTPS (i.e. subunit dissociation) (Haga and Haga, 1992). It has been suggested that such an inhibitory effect is due to a competition between trimeric G proteins and receptor kinases for overlapping sites on the activated receptor. However, the fact that we observed inhibition of betaARK activity toward both an activated receptor (rhodopsin) and a synthetic peptide substrate suggest that, in addition, the interaction of betaARK with the membranes temporarily masks or alters functionally relevant domains of the kinase. The activation of microsomal heterotrimeric G proteins would favor the interaction of free beta subunits with betaARK, which will then adopt an active conformation. Interestingly, the same pattern of modulation of betaARK activity can be detected when stripped plasma membranes were used instead of microsomal membranes, thus suggesting a general feature of betaARK interaction with cellular membranes. Our results confirm, for the first time using physiological membrane preparations, that beta subunits activate betaARK-mediated phosphorylation (Haga and Haga, 1990, 1992; Pitcher et al., 1992; Kameyama et al., 1993; Kim et al., 1993b). Furthermore, we show that betaARK activity can be modulated by endogenous G proteins in different intracellular locations. The fact that G protein stimulation also increases betaARK activity toward a soluble peptide substrate is in line with recent in vitro results showing that phosphorylation of soluble substrates by betaARK or related kinases is enhanced in the presence of beta subunits (Haga et al., 1994b; Kim et al., 1993b). Interestingly, such results are obtained in the presence of putative synergistic modulators of the kinase (activated receptors, synthetic receptor fragments, mastoparan) but not in its absence (Pitcher et al., 1992; Kim et al., 1993b). Taken together, these data suggest that G protein beta subunits stimulate the enzymatic activity of betaARK, in addition to its possible role as a membrane anchor for the kinase (Haga et al. 1994a, 1994b; also see below).

Our results using either plasma or microsomal membranes support a clear distinction between the process of betaARK association with cellular membranes and that of kinase activation. Since the association of betaARK with cellular membranes does not require G protein stimulation, it could take place under resting, basal conditions, whereas betaARK activation leading to substrate phosphorylation would be dependent on the stimulation of G proteins by specific signals. This is consistent with previous data showing that betaARK associates equally well to the heterotrimeric G protein or to the beta dimer alone, thus leading to the suggestion that betaARK targeting to the plasma membrane may take place prior to receptor activation (Kim et al., 1993b).

A key issue to be addressed is the identity of the protein(s) involved in the association of betaARK with the microsomal membranes. To date, betaARK1 has been reported to interact with the activated beta(2)AR and with beta dimers, which have been proposed to play a key role in the kinase targeting to the periphery of the plasma membrane (Pitcher et al., 1992; Kim et al., 1993b). The presence of beta subunits in our salt-stripped microsomal membrane preparation argued for a role of these proteins in betaARK association. The fact that G protein stimulators did not have any effect on S-labeled betaARK binding did not rule out its participation, since it has been previously shown that the activation of purified G(i)/G(o) proteins does not modulate the kinase binding to heterotrimeric G proteins, which could be an entity recognized by betaARK (Kim et al., 1993b). On the other hand, the functional link between membrane-bound betaARK and activated G proteins discussed above does not necessarily imply G proteins as the only anchors of betaARK, since (as mentioned under ``Results'') betaARK could also be binding to a different protein in the stripped microsomes, and its activity modulated by additional interactions with beta subunits released upon G protein stimulation.

Two main lines of evidence support the notion of a binding site for betaARK other than G protein subunits. First, the lack of effect on betaARK association of membrane pretreatment with Na(2)CO(3) pH 11, which leads to an 50% reduction in immunoreactive G proteins (Kehlenbach et al.(1994) and Fig. 4C). Second, the effect of different GST-betaARK fusion proteins on betaARK binding. It has been described that the carboxyl-terminal portion of betaARK-1 is responsible for the activation by G protein beta subunits and that the minimal beta binding domain is localized to a 125-amino acid stretch (Koch et al., 1993; Kameyama et al., 1993). This region partially overlaps with a pleckstrin homology domain present in betaARK (Touhara et al., 1994). It is worth noting that, although pleckstrin homology domains have been recently reported to interact with phospholipid vesicles rich in phosphatidylinositol 4,5-bisphosphate (Harlan et al., 1994), this does not appear to play a predominant role in the interaction of betaARK with microsomal membranes, since we have previously shown that the association is heat and protease-sensitive and therefore involves a protein component of the microsomes (García-Higuera et al., 1994a). Interestingly, our results show that GST-FP2, a fusion protein containing the COOH terminus of betaARK which has been used by others to characterize betaARK interactions with beta subunits (Pitcher et al., 1992; Inglese et al., 1994; Touhara et al., 1994), does not inhibit betaARK1 binding to microsomal membranes, whereas it is able to interact with purified beta subunits (Fig. 8B) and to inhibit the beta effect on rhodopsin phosphorylation by betaARK (Fig. 8C). In agreement with these results, recent experiments (^2)indicate that purified phosducin, which is able to interact with G protein beta subunits (DebBurman et al., 1995) does not inhibit betaARK binding to microsomal membranes in our experimental conditions (94 ± 12% of control binding at 300-450 nM phosducin, mean ± S.E. of four experiments). On the contrary, a fusion protein containing an NH(2)-terminal portion of the kinase (residues 50-145) which does not bind purified beta subunits (FP1), strongly inhibits betaARK association with a potency similar to other reported effects of betaARK fragments (Koch et al., 1993, 1994; Inglese et al., 1994; Touhara et al., 1994). A similar inhibitory effect on betaARK binding can be observed with a GST-betaARK fusion protein comprising amino acids 1-147, whereas a 1-88 fragment is without effect, thus suggesting the betaARK anchoring domain may reside within residues 88-145.

Although at present we cannot totally exclude the possibility that intact G proteins or specific beta dimers play a role in betaARK association with microsomal membranes, we feel that our data strongly suggest that betaARK binding is preferentially mediated via a high affinity interaction with a currently unidentified microsomal protein. As shown in the model depicted in Fig. 10, such protein component (X) appears to interact with a region of the amino terminus of the kinase, thus suggesting a new targeting domain of betaARK. Bound betaARK would be inactive until G protein stimulation leads to additional interactions of the COOH terminus of betaARK with beta-subunits. In line with other recent results, our data suggest that the regulation of betaARK activity and subcellular distribution will likely involve multiple interactions with G protein subunits, phospholipids (DebBurman et al., 1995), different domains of G protein-coupled receptors (Haga et al., 1994b; Ruiz-Gómez et al., 1994), and additional anchoring proteins. In this regard, the existence of anchor proteins has been previously reported for other protein kinases such as protein kinase A (Hausken et al.(1994) and references therein) and protein kinase C (Ron et al., 1994), and emerges as a general mechanism for regulating the subcellular distribution and activity of protein kinases (Mochly-Rosen, 1995). Future research will strive to identify the betaARK anchor protein in the microsomes, and to more precisely localize the betaARK binding domain. Although it has been suggested that the NH(2) terminus of GRKs may interact with activated receptors (Palczewski et al., 1993), (^3)there is little knowledge on the role of this domain, which does not have significant sequence homology with other known GRKs, including GRK1, GRK6, and GRK5, which have been shown to display a different mechanism of membrane association (Kunapuli et al., 1994). Further investigation using different experimental approaches would be needed to ascertain the factors (expression of G protein-coupled receptors, specific combinations of heterotrimeric G proteins, kinase anchors . . . ) and mechanisms governing the complex subcellular distribution of this key regulatory kinase and the possible function(s) of betaARK in microsomal membranes (García-Higuera et al., 1994a).


Figure 10: Proposed model for the interaction of betaARK with microsomal membranes and the modulation of the activation of the bound kinase. The domain structure of betaARK indicates the regions from which fusion proteins GST-betaARK 50-145 (FP1) or GST-betaARK 437-689 (FP2) are derived. X, putative anchor protein; alpha, beta, and are heterotrimeric G protein subunits and alpha* denotes G protein activation.




FOOTNOTES

*
This work was supported in part by Direccion General Investigacion Cientifica y Tecnica PB920135, EC Biotech CT-930083-2, Boehringer Ingelheim and Fundación Ramón Areces (to F. M., Jr.), and National Institutes of Health Grant GM44944 (to J. L. B). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

This work is dedicated to the memory of the late Dr. Oscar Menéndez-Avello.

§
Supported by a predoctoral fellowship from Ministerio de Educación y Ciencia.

Current address: Dept. of Medicine, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115.

**
To whom correspondence should be addressed. Tel.: 341-397-4865; Fax: 341-397-4799.

(^1)
The abbreviations used are: betaAR, beta-adrenergic receptor; betaARK-beta-adrenergic receptor kinase; G protein, guanine nucleotide binding protein; GRK, G protein-coupled receptor kinase; GST, glutathione Stransferase; GTPS, guanosine 5`-(3-0-thio)triphosphate; PAGE, polyacrylamide gel electrophoresis; App(NH)p, 5`-adenylylbeta-imidodiphosphate.

(^2)
C. Murga, M. Lohse, and F. Mayor, Jr., unpublished results.

(^3)
J. L. Benovic, unpublished observations.


ACKNOWLEDGEMENTS

We thank R. Sterne-Marr for providing some purified GST-betaARK fusion proteins, M. Sanz for skillful secretarial assistance, Fundación Ramón Areces for institutional support, Prof. F. Mayor for continuous encouragement, and Dr. J. Avila for critical reading of the manuscript.


REFERENCES

  1. Balch, W. E. (1992) Curr. Biol. 2, 157-160 [Medline] [Order article via Infotrieve]
  2. Benovic, J. L., Mayor, F., Jr., Somers, R. L., Caron, M. G., and Lefkowitz R. J. (1986) Nature 321, 869-872 [Medline] [Order article via Infotrieve]
  3. Benovic, J. L., Regan, J. W., Matsui, H., Mayor, F., Jr., Cotecchia, S., Leeb-Lundberg, L. M. F., Caron, M. G., and Lefkowitz, R. J. (1987) J. Biol. Chem. 262, 17251-17253 [Abstract/Free Full Text]
  4. Benovic, J. L., Bouvier, M., Caron, M. G., and Lefkowitz, R. J. (1988) Annu. Rev. Cell Biol. 4, 405-428 [CrossRef]
  5. Benovic J. L., Stone, W. C., Caron, M. G., and Lefkowitz, R. J. (1989a) J. Biol. Chem. 264, 6707-6710 [Abstract/Free Full Text]
  6. Benovic, J. L., Deblasi, A., Stone, W. C., Caron, M. G., and Lefkowitz, R. J. (1989b) Science 246, 235-240 [Medline] [Order article via Infotrieve]
  7. Chida, K., Sagara, H., Suzuki, Y., Murakami, A., Osada, S-I., Ohno, S., Hirosawa, K., and Kuroki, T. (1994) Mol. Cell. Biol. 14, 3782-3790 [Abstract]
  8. Chuang, T. T., Sallese, M., Ambrosini, G., Parruti, G., and De Blasi, A. (1992) J. Biol. Chem. 267, 6886-6892 [Abstract/Free Full Text]
  9. Colombo, M. I., Mayorga, L. S., Casey, P. J., and Stahl, P. D. (1992) Science 255, 1695-1697 [Medline] [Order article via Infotrieve]
  10. De Almeida, J. B., Doherty, J., Ausiello, D. A., and Stow, J. L. (1993) J. Cell Sci. 106, 1239-1248 [Abstract/Free Full Text]
  11. DebBurman, S. K., Ptasienski, J., Boetticher, E., Lomasney, J. W., Benovic, J. L., and Hosey, M. M. (1995) J. Biol. Chem. 270, 5742-5747 [Abstract/Free Full Text]
  12. Dohlman, H. G., Thorner, J., Caron, M. G., and Lefkowitz, R. J. (1991) Annu. Rev. Biochem. 60, 653-688 [CrossRef][Medline] [Order article via Infotrieve]
  13. Finazzi, D., Cassel, D., Donaldson, J. G., and Klausner, R. D. (1994) J. Biol. Chem. 269, 13325-13330 [Abstract/Free Full Text]
  14. Fujiki, Y., Hubbard, A. L., Fowler, S., and Lazarow, P. B. (1982) J. Cell Biol. 93, 97-102 [Abstract]
  15. García-Higuera, I., and Mayor, F., Jr. (1992) FEBS Lett. 302, 61-64 [CrossRef][Medline] [Order article via Infotrieve]
  16. García-Higuera, I., and Mayor, F., Jr. (1994) J. Clin. Invest. 93, 937-943 [Medline] [Order article via Infotrieve]
  17. García-Higuera, I., Penela, P., Murga, C., Egea, G., Bonay, P., Benovic, J. L., and Mayor, F., Jr. (1994a) J. Biol. Chem. 269, 1348-1356 [Abstract/Free Full Text]
  18. Garcia-Higuera, I., Murga, C., Penela, P., Ruiz-G ó mez, A., and Mayor, F., Jr. (1994b) in Cell Signal Transduction, Second Messengers and Protein Phosphorylation in Health and Disease (Municio, A. M., and Miras, M. T., eds) pp. 129-138, Plenum Publishing Co., New York
  19. Haga, K., and Haga, T. (1990) FEBS Lett. 268, 43-47 [CrossRef][Medline] [Order article via Infotrieve]
  20. Haga, K., and Haga, T. (1992) J. Biol. Chem. 267, 2222-2227 [Abstract/Free Full Text]
  21. Haga, T., Haga, K., and Kameyama, K. (1994a) J. Neurochem. 63, 400-412 [Medline] [Order article via Infotrieve]
  22. Haga, K., Kameyama, K., and Haga, T. (1994b) J. Biol. Chem. 269, 12594-12599 [Abstract/Free Full Text]
  23. Harlan, J. E., Hajduk, P. J., Yoon, H. S., and Fesik, S. W. (1994) Nature 371, 168-171 [CrossRef][Medline] [Order article via Infotrieve]
  24. Hausken, Z. E., Coghlan, V. M., Hastings, C. A. S., Reimann, E. M., and Scott, J. D. (1994) J. Biol. Chem. 269, 24245-24251 [Abstract/Free Full Text]
  25. Higashijima, T., Uzu, S., Nakajima, T., and Ross, E. M. (1988) J. Biol. Chem. 263, 6491-6994 [Abstract/Free Full Text]
  26. Inglese, J., Freedman, N. J., Koch, W. J., and Lefkowitz, R. J. (1993) J. Biol. Chem. 268, 23735-23738 [Free Full Text]
  27. Inglese, J., Luttrell, L. M., Iñíguez-Lluhi, J., Touhara, K., Koch, W. J., and Lefkowitz, R. J. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 3637-3641 [Abstract]
  28. Kameyama, K., Haga, K., Haga, T., Kotani, K., Katada, T., and Fukada, Y. (1993) J. Biol. Chem. 268, 7753-7758 [Abstract/Free Full Text]
  29. Katada, T., Bokoch, G. M., Smigel, M. D., Ui, M., and Gilman, A. G. (1984) J. Biol. Chem. 259, 3586-3595 [Abstract/Free Full Text]
  30. Kehlenbach, R. H., Matthey, J., and Huttner, W. (1994) Nature 372, 804-809 [Medline] [Order article via Infotrieve]
  31. Kelleher, D. J., and Johnson, G. L. (1988) Mol. Pharmacol. 34, 452-460 [Abstract]
  32. Kim, C. M., Dion, S. B., Onorato, J. J., and Benovic, J. L. (1993a) Receptor 3, 39-55 [Medline] [Order article via Infotrieve]
  33. Kim, C. M., Dion, S. B., and Benovic, J. L. (1993b) J. Biol. Chem. 268, 15412-15418 [Abstract/Free Full Text]
  34. Kobilka, B. (1992) Annu. Rev. Neurosci. 15, 87-114 [CrossRef][Medline] [Order article via Infotrieve]
  35. Koch, W. J., Inglese, J., Stone, W. C., and Lefkowitz, R. J. (1993) J. Biol. Chem. 268, 8256-8260 [Abstract/Free Full Text]
  36. Koch, W. J., Hawes, B. E., Inglese, J., Luttrell, L. M., and Lefkowitz, R. J. (1994) J. Biol. Chem. 269, 6193-6197 [Abstract/Free Full Text]
  37. Kunapuli, P., Gurevich, V. V., and Benovic, J. L. (1994) J. Biol. Chem. 269, 10209-10212 [Abstract/Free Full Text]
  38. Kwatra, M., M., Schwinn, D. A., Schreurs, J., Blank, J. L., Kim, C. M., Benovic, J. L., Krause, J. E., Caron, M. G., and Lefkowitz, R. J. (1993) J. Biol. Chem. 268, 9161-9164 [Abstract/Free Full Text]
  39. Lefkowitz, R. J. (1993) Cell 74, 409-412 [Medline] [Order article via Infotrieve]
  40. Lohse, M. J. (1993) Biochim. Biophys. Acta 1179, 171-188 [Medline] [Order article via Infotrieve]
  41. Lohse, M. J., Benovic, J. L., Codina, J., Caron, M. G., and Lefkowitz, R. J. (1990) Science 248, 1547-1550 [Medline] [Order article via Infotrieve]
  42. Loudon, R. P., and Benovic, J. L. (1994) J. Biol. Chem. 269, 22691-22697 [Abstract/Free Full Text]
  43. Mayor, F., Jr., Benovic, J. L., Caron, M. G., and Lefkowitz, R. J. (1987) J. Biol. Chem. 262, 6468-6471 [Abstract/Free Full Text]
  44. Mochly-Rosen, D. (1995) Science 268, 247-251 [Medline] [Order article via Infotrieve]
  45. Müller, S., Hekman, M., and Lohse, M. J. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10439-10443 [Abstract]
  46. Neubig, R. R. (1994) FASEB J. 8, 939-946 [Abstract/Free Full Text]
  47. Northup, J. K., Smigel, M. D., and Gilman, A. G. (1982) J. Biol. Chem. 257, 11416-11423 [Free Full Text]
  48. Nuoffer, C., and Balch, W. E. (1994) Annu. Rev. Biochem. 63, 949-990 [CrossRef][Medline] [Order article via Infotrieve]
  49. Palczewski, K., and Benovic, J. L. (1991) Trends Biochem. Sci. 16, 387-391 [CrossRef][Medline] [Order article via Infotrieve]
  50. Palczewski, K., Buczylko, J., Lebioda, L., Crabb, J. W., and Polans, A. S. (1993) J. Biol. Chem. 268, 6004-6013 [Abstract/Free Full Text]
  51. Pei, S., Tiberi, M., Caron, M. G., and Lefkowitz, R. J. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 3633-3636 [Abstract]
  52. Pitcher, J. A., Inglese, J., Higgins, J. B., Arriza, J. L., Casey, P. J., Kim, C., Benovic, J. L., Kwatra, M. M., Caron, M. G., and Lefkowitz, R. J. (1992) Science 257, 1264-1267 [Medline] [Order article via Infotrieve]
  53. Resh, M. D. (1989) Cell 58, 281-286 [Medline] [Order article via Infotrieve]
  54. Richardson, R. M., Kim, C., Benovic, J. L., and Hosey, M. M. (1993) J. Biol. Chem. 268, 13650-13656 [Abstract/Free Full Text]
  55. Ron, D., Chen., C. H., Caldwell, J., Jamieson, L., Orr, E., and Mochly-Rosen, D. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 839-843 [Abstract]
  56. Ruiz-Gómez, A., Murga, C., de Carlos, J. A., and Mayor, F., Jr. (1994) Soc. Neurosci. Abstr. 20, 1066
  57. Sternweis, P., and Robishaw, J. D. (1984) J. Biol. Chem. 259, 13806-13813 [Abstract/Free Full Text]
  58. Strasser, R. H., Benovic, J. L., Caron, M. G., and Lefkowitz, R. J. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 6362-6366 [Abstract]
  59. Thissen, J. A., and Casey, P. J. (1993) J. Biol. Chem. 268, 13780-13783 [Abstract/Free Full Text]
  60. Touhara, K., Inglese, J., Pitcher, J. A., Shaw, G., and Lefkowitz, R. J. (1994) J. Biol. Chem. 269, 10217-10220 [Abstract/Free Full Text]
  61. Tsai, S.-C., Adamik, R., Haun, R. S., Moss, J., and Vaughan, M. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 9272-976 [Abstract]
  62. Yu, H., Toyoshima, I., Steuer, E. R., and Sheetz, M. P. (1992) J. Biol. Chem. 267, 20457-20464 [Abstract/Free Full Text]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.